+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 60Years - 85Years
All Genders
ID05924425

Study on Daridorexant for Improving Sleep in People Aged 60 to 85 with Mild Cognitive Impairment or Mild to Moderate Alzheimers Disease and Insomnia

Led by University Hospital, Montpellier · Updated on 2026-06-25

62

Participants Needed

1

Research Sites

43 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of daridorexant, a selective dual orexin receptor antagonist, in people aged 60 to 85 years who have mild cognitive impairment MCI or mild to moderate Alzheimers disease AD along with insomnia complaints. This phase IV clinical trial aims to assess both the safety and efficacy of daridorexant in improving sleep in these populations. The study uses a randomized, double-blind, placebo-controlled crossover design to compare daridorexant with placebo. Participants will undergo two one-month treatment periods, receiving either daridorexant 50 mg or a matching placebo each evening within 30 minutes of bedtime. These periods are separated by a washout phase of 5 to 12 days at home. Before randomization, a baseline full-night polysomnography PSG is performed. After completing the crossover phases, participants are invited to join a ten-month open-label study where all receive daridorexant 50 mg. During the study, participants will have PSG recordings at baseline and at the end of each treatment period to measure sleep parameters such as total sleep time and wake time after sleep onset. Additional assessments include neuropsychological tests, sleep and behavior questionnaires, actimetrics monitoring, blood pressure evaluations, and biomarker analysis from blood and cerebrospinal fluid. Researchers will monitor changes in sleep, cognition, biomarkers, and safety outcomes throughout the study, which lasts over one year including the open-label phase.

CONDITIONS

Brief Title

Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease

Research Team

Y

Yves Dauvilliers, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here